- Details
- Lauren Harshman, MD, Alicia Morgans, MD and Toni Choueiri, MD discuss combination therapy for the management of metastatic kidney cancer with the recent approval of pembrolizumab plus axitinib. The combination was approved for all patients regardless of risk category. This adds to the treatment armamentarium for metastatic kidney cancer with the already approved nivolumab plus ipilimumab regimen....
|
- Details
- Thomas Powles discusses the results of the phase III KEYNOTE-426 trial presented at the 2019 Genitourinary Cancers Symposium with Charles Ryan. The checkpoint inhibitor pembrolizumab plus the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor axitinib significantly improved overall survival, progression-free survival, and objective response rates vs sunitinib as first-line therapy...
|
- Details
- Rana McKay, MD reviews the evolving landscape for the frontline treatment of metastatic RCC. Historically, patients were treated with first-line TKIs although the paradigm has been shifting over the past two years including, VEGF targeted therapy with immunotherapy and IO-IO combinations. Dr. McKay reviews the data from KEYNOTE 426 with pembrolizumab plus axitinib which demonstrated a survival ben...
|
- Details
- Sandy Srinivas, MD discusses the frontline data from the KEYNOTE 426 trial comparing pembrolizumab plus axitinib to sunitinib monotherapy in clear cell kidney cancer. 800 patients were randomized and the combination demonstrated benefit across all three outcomes measured including response rates, PFS and overall survival. Dr. Srinivas believes the tolerability for pembrolizumab plus axitinib is mo...
|
- Details
- Primo Lara and Monty Pal discuss this exciting time in the evolving paradigm for the treatment of kidney cancer. They focus their discussion on the groundbreaking data presented at ASCO GU on the KEYNOTE 426 trial which demonstrated that the combination of pembrolizumab plus axitinib was superior to the VEGF RTKI, sunitinib. Overall survival with the combination demonstrated a 46% reduction in the...
|
- Details
- President of KCCure, Dena Battle joins Monty Pal in a discussion on the management of de novo metastatic kidney cancer and the change in practice from cytoreductive nephrectomy to an option of systemic therapy driven by the results of CARMENA trial. Dena shares the patients perspective on this treatment paradigm which comes from a patient survey her organization put forth answering the question of...
|
- Details
- Dena Battle, President KCCure joins Jaime Landman and Monty Pal for a discussion on development and establishing resources to assist in the fight against kidney cancer. KCCure, is a research organization that funds high-impact, high-risk kidney cancer research through a peer-review processthrough an expert team of kidney cancer specialists, patients, caregivers, and kidney cancer advocates. The gr...
|
- Details
- Dan George and Tian Zhang share their views on monitoring treatment toxicities that patients with renal cell carcinoma may experience. Emphasis is placed on counseling patients on expectations and managing baseline comorbities. Maintaining prescribed treatment schedule while focused on quality of life remains the challenging goal for an effective treatment outcome. Biographies: Tian Zhang, MD, Ass...
|
- Details
- (Length of Discussion: 12 min) Tian Zhang and Charles Ryan highlight recent updates in the NCCN treatment guidelines for kidney cancer resulting from data leading to changes in treatment options. Incorporation of initial diagnosis, disease biology, risk category, and clinical factors assist with selecting the most appropriate therapy for these patients. Biographies: Tian Zhang, MD, Assistant Profe...
|
- Details
- Monty Pal and Charles Ryan discuss systemic therapeutic options and current clinical trials in the renal cell carcinoma space. Monty explains the clinical applications, considering appropriate patient selection and toxicity profile relevant in decision making. Biographies: Sumanta (Monty) Kumar Pal, MD Charles J. Ryan, MD Related Content: Cabozantinib Versus Sunitinib As Initial Targeted Therapy f...
|
